Current Gemcitabine News and Events | Page 2

Current Gemcitabine News and Events, Gemcitabine News Articles.
Sort By: Most Relevant | Most Viewed
Page 2 of 6 | 208 Results
TGen-HonorHealth study: High rate of tumor shrinkage among pancreatic cancer patients
Adding cisplatin to standard gemcitabine/nab-paclitaxel drug treatment provided a very high rate of tumor shrinkage for patients with advanced pancreatic cancer, according to the results of a pilot clinical trial conducted by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen). These statistically significant and clinically meaningful improvements in overall response and survival rates resulted from a phase Ib/II clinical study performed at the HonorHealth Research Institute, a partnership of HonorHealth and TGen. (2017-04-25)

Time-lapse shows how anticancer and antiviral drugs get into cells
Duke scientists have modeled all of the steps by which nucleosides and their analogs are transported into cells by a specific molecule named the concentrative nucleoside transporter or CNT. The finding, published in Nature, provides important structural information that could be used to design smarter, more specific anticancer and antiviral drugs. (2017-04-17)

Bladder Cancer Funding Analyzer launched on bladder cancer website
Bladder Cancer (BLC) is proud to announce the launch of the Bladder Cancer Funding Analyzer (BCFA) on the BLC website. It is a free service that is part of a new suite of online features that have been designed to serve the needs of the bladder cancer research community. (2017-02-16)

Scientists identify aggressive pancreatic cancer cells and their vulnerability
A team from The University of Texas MD Anderson Cancer Center describes this week in the journal Nature a series of preclinical experiments using patient-derived tumor xenografts (PDXs) and mouse models that point to potential treatments for patients with a rapidly-progressing and resistant subgroup of tumor cells. (2017-02-09)

Study establishes new standard of care for pancreatic cancer patients
A combination of two chemotherapy drugs -- gemcitabine and capecitabine -- should be the new standard of care for pancreatic cancer patients who have had surgery to remove their tumor. (2017-01-24)

New approach improves five-year survival for pancreatic cancer patients
A University of Liverpool (UK) led clinical trial has been successful in prolonging survival for pancreatic cancer patients by at least five years as a result of a combination of chemotherapy drugs. (2017-01-24)

Researchers found that certain anti-influenza compounds also inhibit Zika virus infection
Researchers from the University of Helsinki have shown that three anti-influenza compounds effectively inhibit Zika virus infection in human cells. The results provide the foundation for development of the broad-spectrum cell-directed antivirals or their combinations for treatment of Zika and other emerging viral diseases. (2017-01-16)

Advanced soft tissue sarcomas respond to new drug GDC-0575 combined with gemcitabine
Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. Professor Antoine Italiano told the 28th EORTC-NCI-AACR Symposium that combining GDC-0575 with gemcitabine, a cancer-killing drug that is already used for treating sarcomas, proved remarkably effective. (2016-12-01)

A drug that inhibits the Notch signalling process is active in a range of advanced cancers
A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumors; importantly, in rare, less well-studied cancers such as adenoid cystic carcinoma. Dr. Christophe Massard told the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics that the drug LY3039478 was successful in inhibiting the Notch signalling pathway in patients with alterations in the Notch protein. (2016-12-01)

Stanford researchers develop new compound to reduce tumor growth
Researchers at Stanford found that a new cell surface receptor they created is effective at inhibiting cancer growth in mice. (2016-11-28)

First feasibility study of the ESMO-MCBS scale in rare tumor entities
The results of the first study analysing the application of the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) in a real-life context for rare tumour entities, were announced today at the ESMO 2016 Congress in Copenhagen. (2016-10-10)

Significant survival gains from neoadjuvant chemotherapy for high-risk soft tissue sarcoma
Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim analysis that led to the early discontinuation of a trial presented today at the ESMO 2016 Congress in Copenhagen. (2016-10-10)

Necitumumab in NSCLC: Indication of minor added benefit for patients with metastases
In metastatic NSCLC, there is an advantage in overall survival as well as disadvantages in side effects. No conclusions are possible on locally advanced non-metastatic NSCLC. (2016-07-04)

Dialing up chemotherapy for pancreatic cancer with ultrasound
Researchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called 'sonoporation' with the commercially-available chemotherapy compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed. They report some initial results at this week's ASA's 171st meeting in Salt Lake City. (2016-05-25)

Vitamin A may help improve pancreatic cancer chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London. The promising initial results have led to the potential treatment being tested in a new clinical trial. (2016-05-24)

Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after four months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer. (2016-05-03)

Patients with EGFR expressing NSCLC benefit most from necitumumab added to chemotherapy
Patients with epidermal growth factor receptor expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference 2016 in Geneva, Switzerland. (2016-04-15)

Modified flu virus can 'resensitize' resistant pancreatic cancer cells to chemotherapy
A common flu virus could be used to overcome patients' resistance to certain cancer drugs -- and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London (QMUL). (2016-04-14)

Bronchial carcinoma: Added benefit of crizotinib for first-line treatment not proven
In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive. (2016-04-08)

Immune therapy breaks down wall around pancreatic tumors for chemo to attack
In a new preclinical study in Cancer Discovery, researchers from the Abramson Cancer Center at the University of Pennsylvania have uncovered the poorly understood mechanics of how macrophages can be 're-educated' by an experimental immune therapy to help tear down the scaffolding that surrounds and protects pancreas cancer from chemotherapy. (2016-02-29)

Afatinib shows clinical benefit for lung cancer patients with brain metastases
Non-small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival (PFS) and response from the EGFR tyrosine kinase inhibitor (TKI) afatinib compared to standard platinum doublet chemotherapy. (2016-01-25)

The Lancet Oncology: Price of cancer drugs varies by up to 388% between European countries, Australia, and New Zealand
The price of new cancer drugs varies widely (from 28% to 388%) between high-income countries in Europe, Australia, and New Zealand, new research published in The Lancet Oncology has found. (2015-12-03)

Study reveals why chemotherapy may be compromised in patients with pancreatic cancer
A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing gemcitabine's ability to stop tumor growth. (2015-11-11)

FDA approves new therapy for pancreatic cancer patients
Patients with advanced pancreatic cancer now have access to the new FDA approved drug, Onivyde, that produced significant overall survival rates in an international clinical study conducted in part by researchers at HonorHealth Research Institute and the Translational Genomics Research Institute. (2015-10-26)

Western University hopes to use artificial intelligence to improve breast cancer patient outcomes
Western University researchers are working on a way to use artificial intelligence to predict a patient's response to two common chemotherapy medications used to treat breast cancer -- paclitaxel and gemcitabine. Peter Rogan, Ph.D., and a team of researchers, including Stephanie Dorman, Ph.D., and Katherina Baranova, B.M.Sc., at Western's Schulich School of Medicine & Dentistry, are hoping to one day remove the guesswork from breast cancer treatment with this technique. (2015-09-18)

Clinical trial using immunotherapy drug combinations to treat lung cancer appears safe
Pembrolizumab, an immunotherapy drug that unmasks cancer cells and allows the body's immune system to destroy tumors, appears to be safe in treating lung cancers, according to a study by Cancer Treatment Centers of America at Western Regional Medical Center. Dr. Glen Weiss is the first author of the study abstract: Phase Ib/II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) one prior line of therapy. (2015-09-09)

A better way to personalize bladder cancer treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer. In early proof-of-concept research, the team took bladder tumors from individual patients, identified actionable mutations and grafted the tumors into mice. (2015-08-13)

Omega-3 fatty acids may help improve treatment and quality of life in cancer patients
Adding omega-3 fatty acids to anti-tumor medications may improve treatment response and quality of life for cancer patients according to a new study by researchers at the University Hospitals of Leicester in the United Kingdom. (2015-07-28)

Survival benefit with 'fully human' EGFR antibody necitumumab in squamous NSCLC
This week, Lancet Oncology reports results of a 1,093-person phase III clinical trial of the drug Necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone. (2015-06-10)

CTCA at Western Regional Medical Center launches Phase II of PembroPlus clinical trial
This innovative 'PembroPlus' clinical trial combines an immunotherapy drug (pembrolizumab) with already FDA-approved chemotherapy drugs (gemcitabine, docetaxel, nab-paclitaxel, vinorelbine, irinotecan, and/or liposomal doxorubicin). The addition of pembrolizumab is aimed at activating the body's own immune system to improve the results that otherwise might be achieved from chemotherapy alone. This combination of chemotherapy drugs is investigational in this study. (2015-04-28)

Fox Chase researchers reveal how pancreatic cancer cells sidestep chemotherapy
Research led by Timothy J. Yen, Ph.D., professor at Fox Chase Cancer Center, reveals that one reason pancreatic cancer can be so challenging to treat is because its cells have found a way to sidestep chemotherapy. They hijack the vitamin D receptor, normally associated with bone health, and re-purposed it to repair the damage caused by chemotherapy. (2015-01-29)

Toughest breast cancer may have met its match
Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Instead, doctors are left with treating these patients with traditional chemotherapy drugs that only show long-term effectiveness in 20 percent of women with triple-negative breast cancer. (2014-12-08)

Customising chemotherapy in Lu Ca: New Ph II data reported in 2 LB studies
Measuring the expression levels of an enzyme involved in DNA synthesis can help predict the response of lung cancers to certain treatments, a Korean study has shown at the ESMO 2014 Congress in Madrid. (2014-09-27)

Wild berry extract may strengthen effectiveness of pancreatic cancer drug
A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals research published online in the Journal of Clinical Pathology. (2014-09-17)

Wild berry extract may strengthen effectiveness of pancreatic cancer drug
A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals experimental research published online in the Journal of Clinical Pathology. (2014-09-17)

Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer
For patients with locally advanced pancreatic cancer, the combination of chemotherapy and stereotactic ablative radiation may be a promising treatment option, ultimately allowing them to undergo surgery that may not otherwise be an option, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. (2014-09-16)

Clinical trial tests COXEN model to predict best treatment for bladder cancer
A computer model, COXEN, matches cancer genetics to best treatments. It is now in a national clinical trial for bladder cancer. (2014-08-13)

New trick for 'old' drug brings hope for pancreatic cancer patients
Scientists have found a new use for an old drug by showing that it shrinks a particular type of pancreatic cancer tumor and stops it spreading. (2014-08-03)

New therapeutic combination to slow resistant sarcomas
Researchers at sarcomas research group at the Bellvitge Biomedical Research Institute and the Catalan Institute of Oncology have been tested in 19 patients a new therapeutic combination to combat resistant sarcomas. The clinical trial results, which indicate that the new treatment could stabilize the growth of these tumors have been published this week in the British Journal of Cancer. (2014-07-10)

MM-398 added to standard treatment shows survival benefit in mets pancreatic cancer
Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. (2014-06-25)

Page 2 of 6 | 208 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to